Selexipag is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Selexipag is a selective prostacyclin receptor agonist. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects. New zero order and first derivative spectrophotometric methods have been proposed for the determination of Selexipag in pharmaceutical formulations. Selexipag obeys Beer-Lambert's law over the concentration range 10–60 μg/ml for all the above mentioned methods and all the methods are validated as per ICH guidelines.
No takes yet. Share an insight, caveat, or question.
Prathyusha et al. (2020) studied this question.